Under the terms of this agreement Biocon will be responsible for the manufacturing and supply of Liraglutide to Zentiva, for its commercialization across 30 countries in Europe
Ryzneuta is a novel dimeric G- CSF long-acting fusion protein without pegylation. The Biologics License Application (BLA) of Ryzneuta is currently under late-stage review by the US FDA for Chemotherapy-Induced Neutropenia (CIN)
If approved, TAK-003 has the potential to become an important dengue prevention option for healthcare providers
The company will reduce wastage substantially, increase productivity, enhance environmental consciousness, save energy, optimally use natural resources, and expand its market penetration
Nifedipine Extended-Release Tablets have an estimated market size of US $56 million for twelve months ending September 2022
The proceeds from this fund-raise will be deployed in financing the project requirements of the API business
Acquisition expands Merck’s growing hematology portfolio
The company offers a wide portfolio of services including integrated doctor-led prescription e-commerce enablement, digital health record management, and smart clinics.
The company had responded to the agency and carried out the required corrective actions.
The approval further strengthens the Potassium Chloride franchise for the company.
Subscribe To Our Newsletter & Stay Updated
